Loading...

DARE DARE BIOSCIENCE INC Contract Awards 8-K Filing

DR B

DR

DARE BIOSCIENCE INC

(DARE)

2023 8-K

Show Summary

Summary

Clinical Trials

Rights Offerings

Investor Meetings

Earnings Releases

Nasdaq Compliance Extension

Financial Results

Nasdaq Delisting Notice

Investor Presentation

Corporate Presentation

Clinical Study Plans

Financial Results

Investor Presentation

Funding Agreement

Stock Purchase Agreement

Financial Results

Compliance regained with Na...

Reverse Stock Split

Annual Meeting of Stockholders

Earnings Report

Agreements with XOMA

Financial Results Announcement

Management Changes

Corporate Presentation

Royalty Interest Financing ...

Phase 1 Clinical Study Results

Changes in Registrant's Cer...

Financial Results Announcement

Phase 2b RESPOND study resu...

Commercial Milestone Achiev...

Financial Results and Audit...

Forced Delisting

Contract Renewal

Annual Meeting of Stockholders

Clinical Trial Results

Earnings Reports

Sales Agreement

Earnings Reports

Presentation Release

Presentation Release

By-laws Amendment

Compliance with Nasdaq Mini...

Clinical Study Results

External Links:

Dare Bioscience, Inc. amends exclusive license agreement with Organon International GmbH to receive a payment of $1.0 million for PDUFA fees and other expenses and $1.8 million after the first commercial sale of Xaciato in the US.

AI Assistant

DARE BIOSCIENCE INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.